Pharmacy adherence pilot boosted refills 36%

Share this article:
Pharmacies that counseled patients for a chronic COPD/respiratory drug saw an average increase in refill rates of more than 36% through the fifth fill, said McKesson.

Counseling for a 90-day smoking cessation drug prompted a 30% increase in refill rates.

The company is piloting an adherence counseling program by which pharmacies are reimbursed by manufacturers for conducting five-minute intervention sessions with patients to improve adherence to prescribed drug regimens.

Participating pharmacists receive training in motivational interviewing and other behavioral techniques. In lieu of a script, they are given branded and unbranded “intervention tools” such as sample questions and responses to guide conversations with patients. Pharmacists, said McKesson, “were compensated in line with fair market value principles established  by the industry,” and the firm monitors transactional and performance data to safeguard against misreporting.

McKesson declined to name the two manufacturers that participated in the pilot but said tey'll be expanding the program to other chronic brands and that the company expects to add a number of brands with new clients to the program in 2010.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...